Лучшие больницы для «Uterosacral Nerve Ablation (LUNA)» в Хайдарабад, Индия

The total cost of Uterosacral Nerve Ablation (LUNA) in India ranges from approximately USD 1,200 to USD 2,500 at NABH- and JCI-accredited hospitals. This all-inclusive package typically covers the surgeon's fee, anaesthesiologist's fee, operating theatre charges, 1–2 nights of hospital accommodation, standard post-operative medications, and discharge consumables. In the UAE (Dubai and Abu Dhabi), the equivalent procedure at JCI- and DHA-accredited hospitals costs between approximately USD 3,000 and USD 6,000, reflecting higher hospital overhead, luxury facility standards, and premium service infrastructure. India is therefore approximately 50–65% more cost-effective than the UAE for this procedure, with no compromise in surgical technique or safety standards — both destinations utilize the same laparoscopic and robotic platforms and employ surgeons with international training credentials. Additional costs not included in these estimates are international airfare, accommodation outside the hospital (GAF Healthcare negotiates preferential rates for partner hotels), and any additional diagnostic tests required pre-operatively. GAF Healthcare provides a fully itemized, no-obligation cost estimate specific to your medical profile before you commit to travel.

Most patients who undergo laparoscopic LUNA as a standalone or combined procedure are fit to fly internationally within 7–10 days of their surgery. Here is what that timeline looks like in practice: you will typically spend 1–2 nights in the hospital post-procedure, followed by 5–7 days of in-country recovery at your partner accommodation arranged by GAF Healthcare. At your Day 5–7 follow-up clinic visit, your gynecologist performs a wound assessment, reviews any biopsy results, and evaluates bladder and bowel function before issuing a formal fit-to-fly clearance. The key clinical milestones that must be met before international travel are approved are: complete wound healing of laparoscopic port sites (typically 5 mm and 10 mm incisions), absence of urinary retention or incomplete bladder emptying (critical given the risk of transient parasympathetic disruption post-LUNA), no signs of infection (normal temperature, no discharge), and satisfactory pain control on oral analgesics alone. Long-haul flights (over 6–8 hours) carry an inherent risk of deep vein thrombosis (DVT) in the post-surgical period; your surgeon will advise on LMWH prophylaxis (e.g., enoxaparin injection) or compression stockings for the return flight. Patients who had a combined procedure (LUNA + extensive endometriosis excision or adhesiolysis) may require 10–14 days in-country before clearance. GAF Healthcare builds this recovery buffer into your treatment itinerary from Day 1.

The success rate of LUNA depends critically on how it is used and in which patient population. When LUNA is performed as an adjunct to laparoscopic excision of endometriosis (the current evidence-based standard of care), patients experience meaningful dysmenorrhea relief in approximately 60–70% of cases at 12 months post-procedure, with several published series reporting NRS (Numeric Rating Scale) pain score reductions of 40–60%. In women with primary dysmenorrhea (no identifiable pelvic pathology), short-to-medium term success rates are similarly reported at 60–75% in prospective studies. It is critically important to understand that multiple high-quality randomized controlled trials — including those reviewed in the Cochrane Database of Systematic Reviews — have demonstrated that LUNA as a standalone procedure, without concurrent treatment of endometriosis, does not significantly outperform diagnostic laparoscopy alone for long-term pain relief in women with endometriosis-associated dysmenorrhea. This is why all GAF Healthcare partner institutions perform LUNA only within a comprehensive surgical plan that includes excision of any identified endometriotic lesions, and all patients receive postoperative medical suppression therapy (most commonly dienogest 2 mg/day or a levonorgestrel IUS) to consolidate surgical outcomes. Pain recurrence rates of 30–40% have been reported at 24 months if the underlying pathology is not fully addressed, underscoring the importance of individualized treatment planning and structured long-term follow-up — both of which are built into GAF Healthcare's post-treatment teleconsultation program.